# Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
# 翰思艾泰生物醫藥科技（武漢）股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 3378)**

## VOLUNTARY ANNOUNCEMENT
## INCLUSION OF HANX BIOPHARMACEUTICALS IN THE FTSE GLOBAL MICRO CAP INDEX

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (the "**Company**" or "**Hanx Biopharmaceuticals**") on a voluntary basis.

The Board is pleased to announce that, based on the FTSE Russell's quarterly review results of the FTSE Global Equity Index Series, Hanx Biopharmaceuticals has been included in the FTSE Global Micro Cap Index (the "**Inclusion**"). The Inclusion officially took effect after the market close on June 19, 2026 (Friday).

The FTSE Global Equity Index Series provides a robust global equity index framework with over 19,000 large-, mid-, small- and micro-cap securities across 49 developed and emerging markets globally, and is one of the widely recognized benchmark indices globally.

The Board believes that the Company's inclusion in the FTSE Global Micro Cap Index marks widespread recognition by the international capital market of its solid fundamentals, innovative capabilities, and growth potential. The Inclusion is expected to enhance the Company's profile among global institutional investors and analysts, attract capital inflows from passive and active funds tracking the relevant index, further diversify its shareholder base, and improve the market liquidity of its shares.

**About Hanx Biopharmaceuticals**

Established in 2014, HanX Biopharmaceuticals (Wuhan) Co., Ltd. is an innovative biotechnology company dedicated to structural biology, translational medicine, and clinical development. The company strives to develop next-generation immunotherapies to provide global patients with affordable, safe, and effective medical solutions, addressing the challenges of major diseases. Guided by a mission and vision driven by innovation, HanX Biopharmaceuticals focuses on discovering, developing, and commercializing First-in-Class and Best-in-Class therapies for cancer and autoimmune diseases. The company is committed to meeting unmet medical needs worldwide, advancing disease prevention, control, and ultimately elimination, and contributing to global health initiatives.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board
**Hanx Biopharmaceuticals (Wuhan) Co., Ltd.**
**Dr. ZHANG Faming**
*Chairman and Executive Director*

Hong Kong, June 22, 2026

*As at the date of this announcement, the Company's Board comprises (i) Dr. Zhang Faming, Dr. Henry Qixiang Li, Ms. Xiao Jieyu and Mr. Liu Min as executive Directors; (ii) Dr. Li Jian as a non-executive Director; and (iii) Dr. Bi Honggang, Mr. Chen Qifeng, Mr. Wong Sai Hung and Dr. Zhang Qiongguang as independent non-executive Directors.*